Most importantly, 31 showed outstandingantiparkinsonian-like activity, being able to reverse haloperidol-inducedcatalepsy at a dose as low as 0.04 mg/kg p.o. These activities wereclearly superior compared to the clinical drugs stimulating the 5-HT1A receptor, including gepirone, recently approved as an antidepressant.Moreover, in view of the substantial comorbidity of depression withParkinson’s disease,38 novel chemicalentities that exhibit both antidepressant and antiparkinsonian activitycould have considerable therapeutic interest. This evidence concerns the gene HTR1A and depressive disorder.